Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
56.19
+1.09 (+1.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
557,042
Open
54.72
Bid (Size)
55.50 (10)
Ask (Size)
59.98 (1)
Prev. Close
55.10
Today's Range
54.68 - 56.74
52wk Range
31.52 - 60.37
Shares Outstanding
70,814,462
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
October 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
October 03, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Performance
YTD
+16.65%
+16.65%
1 Month
-5.34%
-5.34%
3 Month
+26.38%
+26.38%
6 Month
+31.07%
+31.07%
1 Year
+51.78%
+51.78%
More News
Read More
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
September 26, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
September 20, 2024
Via
Benzinga
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
July 22, 2024
Via
Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Participate in Investor Conferences in September
August 29, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
Via
InvestorPlace
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Via
Investor's Business Daily
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
Via
InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
June 11, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.